Day: July 3, 2025

Resonance AI Framework by CapgeminiResonance AI Framework by Capgemini. In an era of unprecedented transformation, AI can release waves of opportunities across industries, ranging from performance improvement to breakthrough innovation and business reinvention.Press contact:Mollie MellowsPhone:+ 44 (0) 7342 709384E-mail: mollie.mellows@capgemini.com Capgemini unveils strategic AI framework to turn enterprise ambition into measurable business impact Paris, July 3, 2025 – Capgemini today unveiled its Resonance AI Framework to help organizations unlock the full potential of AI at scale, reimagining their business from operations to innovation. With the vast majority of organizations planning to implement agentic AI in the next 2 years1, there is a strong need to reinforce organizations’ AI readiness, while creating the right “human-AI...

Sampo plc, stock exchange release, 3 July 2025 at 9:35 am EEST Sampo plc: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act. The reason for the notification by BlackRock, Inc. is the Group restructure following the acquisition of HPS Investment Partners (“HPS”). The aggregate holdings including financial instruments according to SMA 9:6a owned by BlackRock, Inc. and the entities referred to above amounts to 7.00 per cent of the total number of shares and 6.98 per cent of the total voting rights of Sampo plc. Sampo’s share capital comprises 2,691,238,860 shares, of which 2,690,238,860 are A shares and 1,000,000 are B shares. Each A share entitles its holder to one (1) vote and each...

Hexagon Purus ASA’s second quarter results 2025 will be released on 17 July 2025, 07:00 CET. Morten Holum (CEO) and Salman Alam (CFO) will present the results at 08:30 CET and the presentation will be broadcasted live via https://hexagonpurus.vivida.live. The presentation will be held in English and will be virtual. A recording of the presentation will be made available on www.hexagonpurus.com. For more information: Mathias Meidell, IR Director, Hexagon Purus ASATelephone: +47 909 82 242 | mathias.meidell@hexagonpurus.com Salman Alam, CFO, Hexagon Purus ASA Telephone: +47 476 12 713 | salman.alam@hexagonpurus.com About Hexagon Purus ASA Hexagon Purus enables zero emission mobility for a cleaner energy future. The company is a world leading provider of hydrogen Type 4 high-pressure cylinders and systems, battery systems and vehicle...

In June 2025 AS Tallink Grupp transported 598,977 passengers, which is a 4.9% increase compared to June 2024. The number of cargo units decreased by 11.2% to 22,544 units and the number of passenger vehicles was up by 1.0% amounting to 87,530 units compared to the same period a year ago.  In the second quarter of the year (April – June) AS Tallink Grupp transported 1,488,128 passengers, which is a 2.5% increase compared to the previous year. The number of transported cargo units decreased by 22.8% to 67,038 units and the number of passenger vehicles was up by 1.4% to 212,782 units compared to the same period a year ago. AS Tallink Grupp passenger, cargo unit and passenger vehicle numbers for June 2025 and the second quarter of the year were the following:  June 2025 June 2024 Change Q2 2025 Q2 2024 ChangePassengers 598,977 570,803 4.9% 1,488,128 1,451,768 2.5%Finland...

Kverva, 3 July 2025: The Financial Supervisory Authority of Norway has on 2 July 2025 approved the prospectus prepared by SalMar ASA (the Company) in connection with the listing on the Oslo Stock Exchange of the Company’s two bond issues: (i) NOK 3,250,000,000 senior unsecured green bonds issued 25 January 2025, with maturity 30 January 2030 (with ISIN NO0013467316); and (ii) NOK 1,100,000,000 senior unsecured green bonds issued 25 January 2025, with maturity 30 January 2032 (with ISIN NO0013467324). The prospectus with appendices is available on the Company’s website www.salmar.no. For further information, please contact: Håkon Husby, Head of Investor Relations hakon.husby@salmar.no, +47 936 30 449 This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate. Organon has announced results from the Phase 2 ELENA proof-of-concept, where the drug candidate OG-6219 was evaluated in patients with endometriosis-related pain. The outcomes of the study failed to demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to placebo. Based on the results, Organon plans to discontinue the clinical development program with OG-6219. As part of the 2021 acquisition, Organon acquired Forendo...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx was evaluated in combination with a 26-week steroid taper and compared to placebo plus a 52-week steroid taper. Cosentyx did not demonstrate a statistically significant improvement in sustained remission at Week 52 compared to placebo. While the secondary outcomes did not show statistical superiority, Cosentyx showed numerically better outcomes compared to placebo for cumulative steroid...

Q3 Fiscal 2025 Revenues Issy-les-Moulineaux, France – July 3rd, 2025 Pluxee delivers solid organic growth performance in Q3 Fiscal 2025, in line with full-year objectives HighlightsRobust commercial and topline performance, supported by balanced and resilient business model fueled by multiple growth drivers, maintaining the Group on track to achieve full-year targets 310 million euros Total Revenues in Q3 Fiscal 2025, growing organically by +11.1%, driven by Employee Benefits, up +12.3% organically 270 million euros Operating revenue, up +11.1% organically, more weighted toward Latin America and Rest of the world in line with anticipations 39 million euros Float revenue, growing up +10.8% organically at a slightly stronger pace than expected Continuous execution of M&A strategy, with the signing of the acquisition of MyBenefits...

VANCOUVER, British Columbia, July 03, 2025 (GLOBE NEWSWIRE) — Christina Lake Cannabis Corp. (“CLC” or the “Company“) (CSE: CLC) announced today that it will not be filing its annual financial statements, accompanying management’s discussion and analysis and related chief executive officer (“CEO“) and chief financial officer (“CFO“) certifications for the financial year ended February 28, 2025 (collectively, the “Annual Filings“), within the period prescribed for the filing of such documents under Parts 4, 5 and 6 of National Instrument 51-102 Continuous Disclosure Obligations and pursuant to National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, namely within 120 days of year-end, being June 30, 2025 (the “Filing...